Screener
Celldex Therapeutics CLDX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Sales and maturities of marketable securities | 283,876 | 367,873 |
| Purchases of marketable securities | (462,461) | (274,080) |
| Acquisition of property and equipment | (4,818) | (993) |
| Net cash (used in) provided by investing activities | (183,403) | 92,800 |
| Cash flows from financing activities: | ||
| Net proceeds from stock issuances | 323,832 | — |
| Proceeds from issuance of stock from employee benefit plans | 1,152 | 265 |
| Net cash provided by financing activities | 324,984 | 265 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's investing cash flow?
- Celldex Therapeutics (CLDX) reported investing cash flow of -$255.52M in Q2 2026.
- How has Celldex Therapeutics's investing cash flow changed year-over-year?
- Celldex Therapeutics's investing cash flow decreased by 612.6% year-over-year, from $49.85M to -$255.52M.
- What is the long-term trend for Celldex Therapeutics's investing cash flow?
- Over 3 years (2021 to 2025), Celldex Therapeutics's investing cash flow has grown at a -1.1% compound annual growth rate (CAGR), from -$216.16M to $209.07M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Celldex Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude